ECRI steps into fray following "misrepresentation" of its findings on needlestick-prevention devices
This article was originally published in Clinica
Upset over what it sees as the misrepresentation of its latest evaluation of needlestick-prevention devices (NPDs), ECRI, the US nonprofit health services research agency, has issued a statement emphasising that most of the Becton Dickinson safer needle products it has evaluated offer effective protection against needlestick injuries. There has been "widespread miscommunications and conflict involving manufacturers, labour unions and the media" concerning its report, the agency says.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.